These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 6645796)

  • 1. Characteristics of 3H-cis-flupenthixol binding in rat striatum.
    Murrin LC
    Life Sci; 1983 Nov; 33(22):2179-86. PubMed ID: 6645796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kainic acid lesions dissociate [3H] spiperone and [3H]cis-flupenthixol binding sites in rat striatum.
    Cross AJ; Waddington JL
    Eur J Pharmacol; 1981 May; 71(2-3):327-32. PubMed ID: 7250192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions of dopamine agonists with brain D1 receptors labeled by 3H-antagonists. Evidence for the presence of high and low affinity agonist-binding states.
    Leff SE; Hamblin MW; Creese I
    Mol Pharmacol; 1985 Feb; 27(2):171-83. PubMed ID: 3969066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Further evidence that 3H-cis(Z)flupenthixol binds to the adenylate cyclase-associated dopamine receptor (D-1) in rat corpus striatum.
    Hyttel J
    Psychopharmacology (Berl); 1980 Jan; 67(1):107-9. PubMed ID: 6768074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Similarities between the binding of 3H-piflutixol and 3H-flupentixol to rat striatal dopamine receptors in vitro.
    Hyttel J
    Life Sci; 1981 Feb; 28(5):563-9. PubMed ID: 6111013
    [No Abstract]   [Full Text] [Related]  

  • 6. Specific [3H]piflutixol binding to CHAPS-solubilised rat striatal preparations involves dopamine D-2 but not D-1 binding sites.
    Kilpatrick GJ; Jenner P; Marsden CD
    J Neurochem; 1986 Feb; 46(2):413-21. PubMed ID: 3941314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irreversible interaction of beta-haloalkylamine derivatives with dopamine D1 and D2 receptors.
    Cross AJ; Waddington JL; Ross ST
    Life Sci; 1983 Jun; 32(24):2733-40. PubMed ID: 6222234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 3H-Flupenthixol binding in post-mortem brains of schizophrenics: evidence for a selective increase in dopamine D2 receptors.
    Cross AJ; Crow TJ; Owen F
    Psychopharmacology (Berl); 1981; 74(2):122-4. PubMed ID: 6791218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent increase in striatal dopamine stimulated adenylate cyclase activity persists for more than 6 months but disappears after 1 year following withdrawal from 18 months cis-flupenthixol intake.
    Murugaiah K; Fleminger S; Theodorou A; Jenner P; Marsden CD
    Biochem Pharmacol; 1983 Sep; 32(17):2495-9. PubMed ID: 6684429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of neuroleptics on 3H-haloperidol and 3H-cis(Z)-flupenthixol binding and on adenylate cyclase activity in vitro.
    Hyttel J
    Life Sci; 1978 Aug; 23(6):551-5. PubMed ID: 29194
    [No Abstract]   [Full Text] [Related]  

  • 11. Assay of dopamine receptors with [alpha-3H]flupenthixol.
    Huff RM; Molinoff PB
    J Pharmacol Exp Ther; 1985 Jan; 232(1):57-61. PubMed ID: 3965700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flupentixol and dopamine receptor selectivity.
    Hyttel J
    Psychopharmacology (Berl); 1981; 75(2):217. PubMed ID: 6798610
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacology of binding of 3H-SCH-23390 to D-1 dopaminergic receptor sites in rat striatal tissue.
    Faedda G; Kula NS; Baldessarini RJ
    Biochem Pharmacol; 1989 Feb; 38(3):473-80. PubMed ID: 2563653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alterations in different populations of striatal dopamine receptors produced by 18 months continuous administration of cis- or trans-flupenthixol to rats.
    Murugaiah K; Fleminger S; Hall MD; Theodorou A; Jenner P; Marsden CD
    Neuropharmacology; 1984 Jun; 23(6):599-609. PubMed ID: 6540376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased striatal acetylcholine after 14 months cis-flupenthixol treatment in rats suggests functional supersensitivity of dopamine receptors.
    Murugaiah K; Mann S; Theodorou AE; Jenner P; Marsden CD
    Life Sci; 1982 Jul; 31(2):181-8. PubMed ID: 6889662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of 3H-cis-flupenthixol binding to calf brain membranes.
    Cross AJ; Owen F
    Eur J Pharmacol; 1980 Aug; 65(4):341-7. PubMed ID: 7408943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in apomorphine-induced stereotypy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors, but not with increases in D-1 receptors.
    Fleminger S; Rupniak NM; Hall MD; Jenner P; Marsden CD
    Biochem Pharmacol; 1983 Oct; 32(19):2921-7. PubMed ID: 6138043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repeated treatment with imipramine decreased the number of [3H]piflutixol binding sites in the rat striatum.
    Klimek V; Nielsen M; Maj J
    Eur J Pharmacol; 1985 Feb; 109(1):131-2. PubMed ID: 2859994
    [No Abstract]   [Full Text] [Related]  

  • 19. Characteristics of D-1 dopamine receptors labelled by [3H]fluphenazine in homogenates of rat neostriatum.
    Cincotta M; de Vries DJ; Beart PM
    Neurosci Lett; 1985 Oct; 61(1-2):85-9. PubMed ID: 2867505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irreversible blockade of striatal dopamine receptors in vivo by a derivative of alpha-flupenthixol.
    Schuster DI; Holden WL; Narula AP; Murphy RB
    Eur J Pharmacol; 1982 Feb; 77(4):313-6. PubMed ID: 7060641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.